{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:37Z","timestamp":1787161297953,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"instituto de salud carlos iii","doi-asserted-by":"publisher","award":["FIS19\/01407"],"award-info":[{"award-number":["FIS19\/01407"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"instituto de salud carlos iii","doi-asserted-by":"publisher","award":["INT20\/00080"],"award-info":[{"award-number":["INT20\/00080"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"instituto de salud carlos iii","doi-asserted-by":"publisher","award":["CM19\/00042"],"award-info":[{"award-number":["CM19\/00042"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"instituto de salud carlos iii","doi-asserted-by":"publisher","award":["CD18\/00195"],"award-info":[{"award-number":["CD18\/00195"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013560","name":"gbs\/cidp foundation international","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"gofundme campaign","award":["86547262"],"award-info":[{"award-number":["86547262"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain\u2013Barr\u00e9 syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo\/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      None of the GBS patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100) reacted against the nodo\/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and IgM (11% vs 2.2%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-021-02301-0","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T23:02:25Z","timestamp":1635721345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Autoantibody screening in Guillain\u2013Barr\u00e9 syndrome"],"prefix":"10.1186","volume":"18","author":[{"given":"Cinta","family":"Lleix\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Mart\u00edn-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba","family":"Pascual-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"de Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Diaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Tur\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Homedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Concepci\u00f3n","family":"Jimeno-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Berciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Sedano-Tous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Garc\u00eda-Sobrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pardo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celedonio","family":"M\u00e1rquez-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Rojas-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"Jeric\u00f3-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Mart\u00ednez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Mor\u00eds de la Tassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Dom\u00ednguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ndido","family":"Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"2301_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome. Ann Neurol. 1990;27:S21\u20134.","journal-title":"Ann Neurol"},{"key":"2301_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/brain\/109.6.1115","volume":"109","author":"TE Feasby","year":"1986","unstructured":"Feasby TE, et al. An acute axonal form of Guillain\u2013Barr\u00e9 polyneuropathy. Brain. 1986;109:1115\u201326.","journal-title":"Brain"},{"key":"2301_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"Wakerley BR, Uncini A, Yuki N. Guillain\u2013Barr\u00e9 and Miller Fisher s\u00edndromes\u2014new diagnostic classification. Nat Rev Neurol. 2014;10:537\u201344.","journal-title":"Nat Rev Neurol"},{"key":"2301_CR4","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S. Guillain\u2013Barr\u00e9 syndrome. Lancet (London, England). 2021;397:6736.","journal-title":"Lancet (London, England)"},{"key":"2301_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","volume":"10","author":"B Van Den Berg","year":"2014","unstructured":"Van Den Berg B, et al. Guillain\u2013Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469\u201382.","journal-title":"Nat Rev Neurol"},{"key":"2301_CR6","first-page":"360","volume":"153","author":"L Mart\u00edn-Aguilar","year":"2019","unstructured":"Mart\u00edn-Aguilar L, Pascual-Go\u00f1i E, Querol L. Autoantibodies in immune-mediated inflammatory neuropathies. Med Cl\u00edn (English Ed). 2019;153:360\u20137.","journal-title":"Med Cl\u00edn (English Ed)"},{"key":"2301_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14712598.2018.1468885","volume":"18","author":"P Restrepo-Jim\u00e9nez","year":"2018","unstructured":"Restrepo-Jim\u00e9nez P, et al. The immunotherapy of Guillain\u2013Barr\u00e9 syndrome. Expert Opin Biol Ther. 2018;18:619\u201331.","journal-title":"Expert Opin Biol Ther"},{"key":"2301_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11910-002-0043-0","volume":"2","author":"DM Green","year":"2002","unstructured":"Green DM. Advances in the management of Guillain\u2013Barr\u00e9 syndrome. Curr Neurol Neurosci Rep. 2002;2:541\u20138.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2301_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jneuroim.2010.02.001","volume":"223","author":"K Kaida","year":"2010","unstructured":"Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: mini-review. J Neuroimmunol. 2010;223:5\u201312.","journal-title":"J Neuroimmunol"},{"key":"2301_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JND-150078","volume":"2","author":"D Emilien","year":"2015","unstructured":"Emilien D, Hugh W. Diagnostic utility of auto antibodies in inflammatory nerve disorders. J Neuromuscul Dis. 2015;2:107\u201312.","journal-title":"J Neuromuscul Dis"},{"key":"2301_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ana.410440210","volume":"44","author":"S Kuwabara","year":"1998","unstructured":"Kuwabara S, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain\u2013Barre syndrome. Ann Neurol. 1998;44:202\u20138.","journal-title":"Ann Neurol"},{"key":"2301_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/jnnp.56.2.204","volume":"56","author":"HJ Willison","year":"1993","unstructured":"Willison HJ, Veitch J, Paterson G, Kennedy PGE. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry. 1993;56:204\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2301_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323960","author":"Y Yamagishi","year":"2020","unstructured":"Yamagishi Y, et al. Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain\u2013Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry. 2020. https:\/\/doi.org\/10.1136\/jnnp-2020-323960.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2301_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","volume":"83","author":"YA Rajabally","year":"2012","unstructured":"Rajabally YA, Uncini A. Outcome and its predictors in Guillain\u2013Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry. 2012;83:711\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2301_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","volume":"17","author":"JJ Devaux","year":"2012","unstructured":"Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain\u2013Barr\u00e9 syndrome. J Peripher Nerv Syst. 2012;17:62\u201371.","journal-title":"J Peripher Nerv Syst"},{"key":"2301_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/awq372","volume":"134","author":"H Pr\u00fcss","year":"2011","unstructured":"Pr\u00fcss H, Schwab JM, Derst C, G\u00f6rtzen A, Veh RW. Neurofascin as target of autoantibodies in Guillain\u2013Barr\u00e9 syndrome. Brain. 2011;134:1\u20132.","journal-title":"Brain"},{"key":"2301_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000603","volume":"6","author":"H Stengel","year":"2019","unstructured":"Stengel H, et al. Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol NeuroInflamm. 2019;6:1\u201311.","journal-title":"Neurol Neuroimmunol NeuroInflamm"},{"key":"2301_CR18","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/brain\/aww189","volume":"139","author":"K Doppler","year":"2016","unstructured":"Doppler K, et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain. 2016;139:2617\u201330.","journal-title":"Brain"},{"key":"2301_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000817","author":"L Appeltshauser","year":"2020","unstructured":"Appeltshauser L. Anti-paranodal antibodies and IgG subclasses in acute autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2020. https:\/\/doi.org\/10.1212\/NXI.0000000000000817.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2301_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-1001-8","volume":"14","author":"D Schafflick","year":"2017","unstructured":"Schafflick D, Kieseier BC, Wiendl H, Meyer zu Horste G. Novel pathomechanisms in inflammatory neuropathies. J Neuroinflamm. 2017;14:1\u201317.","journal-title":"J Neuroinflamm"},{"key":"2301_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jns.12209","volume":"22","author":"BC Jacobs","year":"2017","unstructured":"Jacobs BC, et al. International Guillain\u2013Barr\u00e9 Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain\u2013Barr\u00e9 syndrome. J Peripher Nerv Syst. 2017;22:68\u201376.","journal-title":"J Peripher Nerv Syst"},{"key":"2301_CR22","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/brain\/awy232","volume":"141","author":"AY Doets","year":"2018","unstructured":"Doets AY, et al. Regional variation of Guillain\u2013Barr\u00e9 syndrome. Brain. 2018;141:2866\u201377.","journal-title":"Brain"},{"key":"2301_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar JJ, et al. Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599\u2013612.","journal-title":"Vaccine"},{"key":"2301_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"312","author":"RAC Hughes","year":"1978","unstructured":"Hughes RAC, Newsom-Davis J, Perkin G, Pierce J. Controlled trial of prednisolone in acute polyneuropathy. Lancet (London, England). 1978;312:750\u20133.","journal-title":"Lancet (London, England)"},{"key":"2301_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/acn3.554","volume":"5","author":"AM Siles","year":"2018","unstructured":"Siles AM, et al. Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies. Ann Clin Transl Neurol. 2018;5:559\u201369.","journal-title":"Ann Clin Transl Neurol"},{"key":"2301_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1046\/j.1468-1331.1999.610071.x","volume":"6","author":"HJ Willison","year":"1999","unstructured":"Willison HJ, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol. 1999;6:71\u20137.","journal-title":"Eur J Neurol"},{"key":"2301_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/08916930008994083","volume":"32","author":"GM Ohanlon","year":"2000","unstructured":"Ohanlon GM, et al. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity. 2000;32:133\u201344.","journal-title":"Autoimmunity"},{"key":"2301_CR28","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43:W566\u201370.","journal-title":"Nucleic Acids Res"},{"key":"2301_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323899","author":"L Mart\u00edn-Aguilar","year":"2020","unstructured":"Mart\u00edn-Aguilar L, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain\u2013Barr\u00e9 syndrome patients. J Neurol Neurosurg Psychiatry. 2020. https:\/\/doi.org\/10.1136\/jnnp-2020-323899.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2301_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/jnnp.2004.051136","volume":"76","author":"A Hiraga","year":"2005","unstructured":"Hiraga A, et al. Recovery patterns and long term prognosis for axonal Guillain\u2013Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry. 2005;76:719\u201322.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2301_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/jnnp.70.4.560","volume":"70","author":"S Kuwabara","year":"2001","unstructured":"Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N. Indicators of rapid clinical recovery in Guillain\u2013Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry. 2001;70:560\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2301_CR32","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.56.6.758","volume":"56","author":"RDM Hadden","year":"2001","unstructured":"Hadden RDM, et al. Preceding infections, immune factors, and outcome in Guillain\u2013Barr\u00e9 syndrome. Neurology. 2001;56:758\u201365.","journal-title":"Neurology"},{"key":"2301_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1212\/WNL.58.4.610","volume":"58","author":"R Van Koningsveld","year":"2002","unstructured":"Van Koningsveld R, et al. Infections and course of disease in mild forms of Guillain\u2013Barr\u00e9 syndrome. Neurology. 2002;58:610\u20134.","journal-title":"Neurology"},{"key":"2301_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14853-4","volume":"7","author":"L Querol","year":"2017","unstructured":"Querol L, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep. 2017;7:1\u20139.","journal-title":"Sci Rep"},{"key":"2301_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","volume":"13","author":"L Querol","year":"2017","unstructured":"Querol L, Devaux J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13:533\u201347.","journal-title":"Nat Rev Neurol"},{"key":"2301_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/brain\/awg030","volume":"126","author":"MSG Kwa","year":"2003","unstructured":"Kwa MSG, et al. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain. 2003;126:361\u201375.","journal-title":"Brain"},{"key":"2301_CR37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ene.14133","volume":"27","author":"JM Vallat","year":"2020","unstructured":"Vallat JM, et al. Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates. Eur J Neurol. 2020;27:692\u2013701.","journal-title":"Eur J Neurol"},{"key":"2301_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard SE, et al. Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019;15:671\u201383.","journal-title":"Nat Rev Neurol"},{"key":"2301_CR39","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/WNL.57.7.1316","volume":"57","author":"CL Pan","year":"2001","unstructured":"Pan CL, Yuki N, Koga M, Chiang MC, Hsieh ST. Acute sensory ataxic neuropathy associated with monospecific anti-GD1B IgG antibody. Neurology. 2001;57:1316\u20138.","journal-title":"Neurology"},{"key":"2301_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0165-5728(98)00016-2","volume":"86","author":"M Koga","year":"1998","unstructured":"Koga M, Yuki N, Ariga T, Morimatsu M, Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain\u2013Barre syndrome? J Neuroimmunol. 1998;86:74\u20139.","journal-title":"J Neuroimmunol"},{"key":"2301_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/1097-4598(200101)24:1<54::AID-MUS6>3.0.CO;2-9","volume":"24","author":"S Kuwabara","year":"2001","unstructured":"Kuwabara S, et al. Intravenous immunoglobulin therapy for Guillain\u2013Barr\u00e9 syndrome ith IgG anti-GM1 antibody. Muscle Nerve. 2001;24:54\u20138.","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02301-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T23:02:34Z","timestamp":1635721354000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02301-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.10.21256964","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.741088187.793593554","asserted-by":"object"}]},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau and the local institutional review boards of participating hospitals or universities. All patients gave written informed consent to participate in the study. Animal procedures were performed according to a protocol approved by our Institution\u2019s Animal Ethics\u2019 Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}